A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of valganciclovir (Valcyte) in patients experiencing chronic fatigue syndrome with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV)

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of valganciclovir (Valcyte) in patients experiencing chronic fatigue syndrome with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2013

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Chronic fatigue syndrome; Epstein-Barr virus infections; Herpesvirus infections
  • Focus Therapeutic Use
  • Acronyms EVOLVE

    • Most Recent Events

    • 30 Aug 2007 Status changed from recruiting to in progress.
    • 25 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top